|
"bai l y"的相關文件
顯示項目 26-50 / 50 (共1頁)
1
每頁顯示[10|25|50]項目
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國立成功大學 |
2022 |
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study
|
Bai, L.-Y.;Li, C.-P.;Shan, Y.-S.;Chuang, S.-C.;Chen, J.-S.;Chiang, N.-J.;Chen, Y.-Y.;Tsou, H.-H.;Chuang, M.-H.;Chiu, Chiu C.-F.;Liu, T.-W.;Chen, L.-T. |
| 臺大學術典藏 |
2021-09-15T01:20:45Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
CHIA-LANG HSU; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Kuo W.-H.; Lin P.-H.; Huang A.-C.; Chien Y.-H.; Liu T.-P.; Lu Y.-S.; Bai L.-Y.; Sargeant A.M.; Lin C.-H.; ANN-LII CHENG; Hsieh F.-J.; Hwu W.-L.; Chang K.-J. |
| 臺大學術典藏 |
2021-06-03T06:15:36Z |
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
|
PO-HAN LIN; Li H.-Y.; Fan S.-C.; Yuan T.-H.; Chen M.; Hsu Y.-H.; Yang Y.-H.; Li L.-Y.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Lin C.-H.; Lien M.-Y.; Chen T.-T.; Ni Y.-H.; Chiu C.-F. |
| 臺大學術典藏 |
2021-01-28T01:06:35Z |
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer
|
Chao Y.;Hsieh J.-S.;Yeh H.-T.;Su Y.-C.;Wu C.-C.;Chen J.-S.;Tai C.-J.;Bai L.-Y.;Kun-Huei Yeh;Su W.-C.;Li C.-P.; Chao Y.; Hsieh J.-S.; Yeh H.-T.; Su Y.-C.; Wu C.-C.; Chen J.-S.; Tai C.-J.; Bai L.-Y.; KUN-HUEI YEH; Su W.-C.; Li C.-P. |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:17Z |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
| 國立成功大學 |
2021 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients
|
Hu, Hu H.-M.;Tsai, H.-J.;Ku, H.-Y.;Lo, S.-S.;Shan, Y.-S.;Chang, H.-C.;Chao, Y.;Chen, J.-S.;Chen, S.-C.;Chiang, Chiang C.-J.;Li, A.F.-Y.;Wang, H.-P.;Wang, T.-E.;Bai, L.-Y.;Wu, M.-S.;Chen, L.-T.;Liu, T.-W.;Yang, Yang Y.-H. |
| 國立成功大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, T.-J.;Su, Y.-Y.;Yang, S.-H.;Li, C.-P.;Bai, L.-Y.;Chiang, N.-J.;Chuang, S.-C.;Shan, Y.-S.;Chan, D.-C.;Chen, L.-T.;Yen, C.-J.;Peng, C.-M.;Chen, Y.-Y.;Chen, J.-S.;Chou, W.-C. |
| 國立成功大學 |
2021 |
Clinical and immunologic responses to a B-Cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer—results from phase Ib trial IMU.ACS.001
|
Wiedermann, U.;Garner-Spitzer, E.;Chao, Y.;Maglakelidze, Maglakelidze M.;Bulat, I.;Dechaphunkul, A.;Arpornwirat, W.;Charoentum, Charoentum C.;Yen, C.-J.;Yau, T.C.;Tanasanvimon, S.;Maneechavakajorn, J.;Sookprasert, A.;Bai, L.-Y.;Chou, W.-C.;Ungtrakul, T.;Drinic, M.;Tobias, J.;Zielinski, C.C.;Chong, L.;Ede, N.J.;Marino, Marino M.T.;Good, A.J. |
| 國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
| 臺大學術典藏 |
2020-12-28T08:14:14Z |
A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
|
Li H.-Y.; Fan S.-C.; Lin P.-H.; YEN-HSUAN NI; Chiu C.-F.; Yuan T.-H.; Chen M.; Hsu Y.-H.; Yang Y.-H.; Li L.-Y.; Yeh S.-P.; Bai L.-Y.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-C.; Lin C.-H.; Lien M.-Y.; Chen T.-T. |
| 臺大學術典藏 |
2020-12-24T06:16:51Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Chang K.-J.; Hwu W.-L.; Hsieh F.-J.; Cheng A.-L.; Lin C.-H.; Sargeant A.M.; Bai L.-Y.; Lu Y.-S.; Liu T.-P.; YIN-HSIU CHIEN; Kuo W.-H.; Lin P.-H.; Huang A.-C. |
| 臺大學術典藏 |
2020-12-16T02:25:38Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Kuo W.-H.; Lin P.-H.; Huang A.-C.; Chien Y.-H.; Liu T.-P.; Lu Y.-S.; Bai L.-Y.; Sargeant A.M.; Lin C.-H.; Cheng A.-L.; Hsieh F.-J.; WUH-LIANG HWU; Chang K.-J. |
| 臺大學術典藏 |
2020-05-25T06:51:59Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Chang K.-J.;Hwu W.-L;Hsieh F.-J;Cheng A.-L;Lin C.-H;Sargeant A.M;Bai L.-Y;Yen-Shen Lu;Liu T.-P;Chien Y.-H;Huang A.-C;Lin P.-H;Kuo W.-H; Kuo W.-H; Lin P.-H; Huang A.-C; Chien Y.-H; Liu T.-P; YEN-SHEN LU; Bai L.-Y; Sargeant A.M; Lin C.-H; Cheng A.-L; Hsieh F.-J; Hwu W.-L; Chang K.-J. |
| 臺大學術典藏 |
2020-03-24T04:02:54Z |
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer
|
Cheng A.-L.; Lin C.-H.; Sargeant A.M.; Lu Y.-S.; Bai L.-Y.; Liu T.-P.; WEN-HUNG KUO; Lin P.-H.; Huang A.-C.; Chien Y.-H.; Hsieh F.-J.; Hwu W.-L.; Chang K.-J. |
| 國立成功大學 |
2020 |
OSU-A9 induced-reactive oxygen species cause cytotoxicity in duodenal and gastric cancer cells by decreasing phosphorylated nuclear pyruvate kinase M2 protein levels
|
Chiu, Chiu C.-F.;Weng, J.-R.;Lee, S.-L.;Wu, C.-Y.;Chu, P.-C.;Shan, Y.-S.;Yang, H.-R.;Bai, L.-Y. |
| 國立成功大學 |
2020 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, L.-T.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Sameshima, H.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2020 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T.;Kang, Y.-K.;Chao, Y.;Ryu, M.-H.;Kato, Kato K.;Cheol, Chung H.;Chen, J.-S.;Muro, K.;Ki, Kang W.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Tanimoto, M.;Chen, L.-T.;Boku, N. |
| 國立成功大學 |
2019 |
Effect of First-line S-1 Plus Oxaliplatin with or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
|
Yoshikawa, T.;Muro, K.;Shitara, K.;Oh, D.-Y.;Kang, Y.-K.;Chung, H.C.;Kudo, T.;Chin, K.;Kadowaki, S.;Hamamoto, Y.;Hironaka, S.;Yoshida, K.;Yen, C.-J.;Omuro, Y.;Bai, L.-Y.;Maeda, K.;Ozeki, A.;Yoshikawa, R.;Kitagawa, Y. |
| 臺大學術典藏 |
2018-09-10T09:51:59Z |
Young nasopharyngeal cancer patients with radiotherapy and chemotherapy are most prone to ischaemic risk of stroke: A national database, controlled cohort study
|
Chu, C.-N. ; Chen, P.-C. ; Bai, L.-Y. ; Muo, C.-H. ; Sung, F.-C. ; Chen, S.-W.; Pau-Chung CHEN |
| 國立成功大學 |
2015-05-01 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, J. S.; Hsu, C.; Chiang, N. J.; Tsai, C. S.; Tsou, H. H.; Huang, S. F.; Bai, L. Y.; Chang, I. C.; Shiah, H. S.; Ho, C. L.; Yen, C. J.; Lee, K. D.; Chiu, C. F.; Rau, K. M.; Yu, M. S.; Yang, Y.; Hsieh, R. K.; Chang, J. Y.; Shan, Y. S.; Chao, Y.; Chen, L. T. |
| 臺大學術典藏 |
2015 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
on behalf of the Taiwan Cooperative Oncology Group; Wei T.-C.; Shan Y.S.; Chao Y.; Chen L.-T.; Chin Y.-H.; Chung T.-R.; Yu W.-L.; Lee M.-H.; Lin L.-F.; Lin P.-C.; Wu Y.-L.; Wang H.-L.; Lu L.-J.; Chen S.-Y.; Wu C.-C.; Chang J.Y.; Yu M.S.; Yang Y.; Hsieh R.K.; Chiu C.F.; Rau K.M.; Lee K.D.; Shiah H.S.; Chang I.C.; Bai L.Y.; Huang S.F.; Tsou H.H.; Tsai C.S.; Chiang N.J.; CHIH-HUNG HSU; Chen J.S.; Chen J.S.;Chih-Hung Hsu;Chiang N.J.;Tsai C.S.;Tsou H.H.;Huang S.F.;Bai L.Y.;Chang I.C.;Shiah H.S.;Ho C.L.;Yen C.J.;Lee K.D.;Chiu C.F.;Rau K.M.;Yu M.S.;Yang Y.;Hsieh R.K.;Chang J.Y.;Shan Y.S.;Chao Y.;Chen L.-T.;Chin Y.-H.;Chung T.-R.;Yu W.-L.;Lee M.-H.;Lin L.-F.;Lin P.-C.;Wu Y.-L.;Wang H.-L.;Lu L.-J.;Chen S.-Y.;Wu C.-C.;Wei T.-C.;On Behalf Of The Taiwan Cooperative Oncology Group; Yen C.J.; Ho C.L. |
顯示項目 26-50 / 50 (共1頁)
1
每頁顯示[10|25|50]項目
|
